Carbamylcholine chloride (Carbachol), CAS 51-83-2, is a quaternary ammonium cholinergic agonist supplied as a veterinary-grade active pharmaceutical ingredient for tablets, injections, capsules, powders, granules, premixes, and solutions. The molecular structure 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride has the molecular formula C6H15ClN2O2 and a relative molecular mass of 182.65. The API is released as a white to off-white crystalline powder or granular material, with particle-size and microbial-quality attributes matched to the intended dosage route rather than to a single powder specification. The direct-compression model is designated CCh-T150 and is controlled to a volume-weighted D90 ≤150 µm for tablet and capsule manufacture. The granular model CCh-G355 is controlled to D90 ≤355 µm for premix and dry granule blending. The parenteral model CCh-ST is controlled to a bacterial endotoxin limit of ≤0.5 EU/mg and is intended for injectable and ophthalmic solution preparation after aseptic filtration or terminal sterilization. These model identifiers describe physical form and route-specific microbial burden; the chemical identity and compendial assay requirements remain identical across all three grades.

Why Does Particle Size Distribution Govern Dose Uniformity and Dissolution in Multi-Route Veterinary Dosage Forms?

For solid oral dosage forms, particle size distribution is a release parameter because carbachol tablets and capsules typically contain a low mass fraction of API. A direct-compression core with 1.0 mg carbachol in a 100 mg tablet has an API fraction of 1.0% w/w; agglomerates above 150 µm can shift individual tablet assay outside the compendial content uniformity acceptance range of 85.0–115.0% described in USP <905> and Ph. Eur. 2.9.40. The CCh-T150 direct-compression grade is therefore milled to a volume-weighted D90 ≤150 µm, with span (D90-D10)/D50 controlled between 1.2 and 2.0 when measured by laser diffraction according to ISO 13320:2020. In a rotary tablet press with forced feeder speeds of 30–80 rpm, finer material with D90 below 45 µm improves blending but may increase dusting and punch adhesion; coarser material with D90 above 355 µm tends to segregate in the feed frame and produce weight variation. Batch uniformity of premix and oral powder blends is assessed on production-scale tumble blenders such as a 600-L double-cone blender operated at 12 rpm; blend assay relative standard deviation is typically targeted at ≤5.0% in development trials. Sieve analysis under USP <786> or Ph. Eur. 2.9.38 is used as the release method for the CCh-G355 granular grade because sieve data correlate more directly with segregation behavior in bulk feed transport than laser diffraction values.

Granule and premix carriers such as lactose monohydrate, dextrose, or pelleted feed binders have broader particle size distributions. If the API is micronized to the tablet grade and then dry-mixed into feed, electrostatic adhesion and dust loss can reduce assay recovery in the final premix; the larger particle size of CCh-G355 reduces dusting during transfer and improves carrier adhesion. For wet granulation processes, the hygroscopic character of carbachol requires a granulation endpoint based on impeller torque rather than fixed time because water uptake shifts mass consistency. A high-shear mixer with impeller speed of 120 rpm and chopper speed of 1,500 rpm is a typical development configuration, but validated loading and wet massing time must be established per formulation. For tablet and capsule dosage forms, dissolution testing under USP <711> or Ph. Eur. 2.9.3 is used to confirm release; because carbachol is freely soluble in aqueous media, a common acceptance criterion may be ≥80% (Q) dissolved in 30 min in 900 mL of water or buffer at 37°C ± 0.5°C with paddle speed 50 rpm, but the exact method must be product-specific.

Chemical purity is controlled independently of the physical model. Reversed-phase HPLC with UV detection at 210 nm is used for assay and related-substance determination, with an octadecylsilane column of 250 mm × 4.6 mm, 5 µm particle size, and a phosphate buffer–acetonitrile gradient. The assay release limit is 99.0–101.0% w/w on the dried, solvent-free basis for all three grades. Total related substances are limited to ≤0.5% area percent; any single unspecified impurity is capped at ≤0.10%, and identification thresholds are assigned according to ICH Q3A for the expected veterinary daily dose. Water content by Karl Fischer titration under USP <921> is limited to ≤1.0% w/w because higher moisture accelerates hydrolytic degradation of the carbamate group and reduces flowability in direct-compression feeding. Residue on ignition is controlled to ≤0.10% under USP <281>. Elemental impurities are managed according to ICH Q3D Option 1; for a veterinary dosage range of 1 mg/day to 10 mg/day, concentration limits for Class 1 elements As, Cd, Hg, and Pb are derived from permitted daily exposure values and reported on the certificate of analysis. Residual solvents are controlled under ICH Q3C; if ethanol or isopropanol is used as the final crystallization solvent, the material is expected to comply with Class 3 residual solvent limits. If acetonitrile is used in the synthesis, the Class 2 limit of 410 ppm applies. For the CCh-ST parenteral grade, bacterial endotoxin is controlled to ≤0.5 EU/mg by USP <85>; for non-sterile oral grades, the total aerobic microbial count is controlled to ≤100 CFU/g by USP <61>, and total combined yeasts and molds to ≤10 CFU/g by USP <62>.

Container Closure and Moisture Barrier Requirements for Hygroscopic Carbachol

The solid API is hygroscopic and is handled in an environment with relative humidity below 40% during dispensing, sieving, and blending. Open-container water uptake at 60% RH can raise water content above the release limit within 24 h. Primary packaging for CCh-T150 and CCh-G355 is an HDPE drum with double low-density polyethylene liners and a silica gel or molecular sieve desiccant. The desiccant mass is calculated to maintain internal headspace relative humidity at ≤25% for a 12-month re-test interval at 25°C ± 2°C/60% RH ± 5% RH. Stability testing follows ICH Q1A(R2), with accelerated storage at 40°C ± 2°C/75% RH ± 5% RH. The CCh-ST parenteral grade is double-bagged and sealed in an aluminum composite bag under nitrogen overlay; headspace oxygen is controlled to below 2.0% v/v by gas analysis before sealing.

For dry blending of premixes, geometric dilution is required because the active mass fraction is typically between 0.1% and 5.0% w/w. A V-blender with an intensifier bar is used for small-scale blending; production-scale ribbon blenders of 500 kg capacity require sequential dilution of carbachol into carrier excipients to achieve a blend relative standard deviation ≤5.0%. In tablet manufacture, the CCh-T150 grade is blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate; magnesium stearate addition is held below 5 min at 1.0% w/w to avoid over-lubrication of the low-dose blend. Compression force is adjusted between 8 kN and 15 kN on a rotary tablet press to produce tablets with hardness 40–80 N and friability below 0.8% w/w when tested under USP <1216>. Capsule filling uses dosator or tamping equipment with fill weight controlled to ±5.0% of target. For injectable solutions, the CCh-ST grade is dissolved in Water for Injection at a pH of 4.5–6.0; the solution is passed through a 0.22 µm sterilizing-grade polyethersulfone filter before aseptic filling. Terminal sterilization may be substituted after validation of assay and related substances at 121°C for 15 min, provided the buffer system does not generate acetate-catalyzed hydrolysis of the carbamate group. For injectable solutions, osmolality is adjusted with sodium chloride to 280–320 mOsm/kg, measured by freezing point depression under USP <785> or Ph. Eur. 2.2.35. For multi-dose ophthalmic presentations, antimicrobial preservative compatibility is formulation-specific; no preservative concentration is assigned without validation against USP <51> antimicrobial effectiveness testing.

When pH and Buffer Capacity Dictate Solution and Premix Stability

The carbamate function in carbachol is susceptible to pH-dependent hydrolysis. Aqueous stability is highest in the weakly acidic range; alkaline pH accelerates nucleophilic attack at the carbonyl carbon. Formulation trials with forced degradation at 80°C for 7 days are used to establish pH sensitivity and to identify degradation products, but published data for this specific configuration is limited, and the observed degradation profile is formulation-dependent. Solutions are therefore buffered with 10–50 mM acetate or citrate buffer to a pH of 4.5–6.0; buffer capacity is selected so that the finished solution remains within ±0.2 pH units after autoclaving or aseptic processing. For oral solutions and liquid premix carriers, propylene glycol at 10%–30% v/v is used to lower water activity, but the final formulation must be checked by HPLC because carbachol can react with nucleophilic buffer components. In solid premixes, the API is incompatible with alkaline fillers such as calcium hydroxide and with strongly oxidizing agents; combination with amine-based binders should be avoided because they can promote nucleophilic substitution at the carbamate carbonyl.

Compared with acetylcholine chloride, carbachol is resistant to hydrolysis by acetylcholinesterase and butyrylcholinesterase because the ester oxygen of acetylcholine is replaced by a carbamate group. This structural change prolongs pharmacological action after topical or parenteral administration, but the quaternary ammonium moiety still limits passive diffusion across lipid membranes. Compared with bethanechol chloride, carbachol has broader direct cholinergic activity; bethanechol is primarily muscarinic, whereas carbachol activates both muscarinic and nicotinic receptors. In isolated tissue organ bath assays, carbachol produces concentration-dependent contraction of ileum and urinary bladder smooth muscle, but the exact EC50 varies by species, tissue, and buffer conditions; direct comparison with bethanechol requires paired agonist curves in the same preparation. This receptor difference explains the more limited systemic tolerance of carbachol in small-animal motility therapy and its continued use in topical ophthalmic and short-duration parenteral veterinary protocols. Compared with pilocarpine hydrochloride, another cholinergic agonist used in veterinary ophthalmology, carbachol is a quaternary ammonium compound; pilocarpine is a tertiary amine with greater corneal penetration and different systemic distribution. For routes where rapid central nervous system penetration is undesirable, the quaternary structure of carbachol reduces distribution to the brain relative to tertiary amines. The difference from a human-grade carbachol reference is not chemical identity but the regulatory master file, veterinary-specific microbial acceptance criteria, premix homogeneity data, and documentation under ICH Q7 and applicable veterinary GMP provisions.